Evans G F, Bensch W R, Apelgren L D, Bailey D, Kauffman R F, Bumol T F, Zuckerman S H
Division of Cardiovascular Research, Lilly Research Labs, Lilly Corporate Center, Indianapolis, IN 46285.
J Lipid Res. 1994 Sep;35(9):1634-45.
The effects of cholesteryl ester transfer protein (CETP) inhibition on the serum lipoprotein profile in both normocholesterolemic and hypercholesterolemic hamsters has been determined following subcutaneous injection of 12.5 mg/kg of the CETP neutralizing monoclonal antibody, TP2. Inhibition of CETP activity was greater than 60% and resulted in a 30-40% increase in high density lipoprotein (HDL) in both normal and hypercholesterolemic animals. These HDL effects were observed 1 day post-injection, were maximal by 4 days, and returned to control values by 14 days. Inhibition of CETP activity resulted in a decrease in both low density lipoprotein (LDL) and very low density lipoprotein (VLDL) cholesterol concomitant with HDL increase, and in hypercholesterolemic animals resulted in increased total serum cholesterol. In addition to the quantitative differences in LDL and HDL, there were significant increases in the size of the HDL, a shift to smaller LDL particles, and changes in apolipoprotein (apo) composition as evaluated by FPLC and Western blot analysis. Large apoA-I-poor and apoE-containing HDL became prevalent in hypercholesterolemic hamsters after CETP inhibition. In addition, the size of the CETP-containing HDL particles increased with inhibition of transfer activity. While these effects were apparent in normocholesterolemic animals, the changes in apolipoprotein distribution and HDL subspecies as detected on native gels were more significant in the hypercholesterolemic animals. The changes in the HDL profile and apolipoprotein distribution after CETP inhibition in hamsters were similar to those reported in CETP-deficient Japanese subjects, suggesting the utility of the hypercholesterolemic hamster as an in vivo model for the understanding of the lipoprotein changes associated with CETP inhibition.
皮下注射12.5 mg/kg的胆固醇酯转运蛋白(CETP)中和单克隆抗体TP2后,已确定CETP抑制对正常胆固醇血症和高胆固醇血症仓鼠血清脂蛋白谱的影响。在正常和高胆固醇血症动物中,CETP活性的抑制率均大于60%,高密度脂蛋白(HDL)增加30 - 40%。这些HDL效应在注射后1天即可观察到,4天时达到最大,14天时恢复到对照值。CETP活性的抑制导致低密度脂蛋白(LDL)和极低密度脂蛋白(VLDL)胆固醇降低,同时HDL增加,在高胆固醇血症动物中导致总血清胆固醇升高。除了LDL和HDL的定量差异外,通过快速蛋白质液相色谱(FPLC)和蛋白质免疫印迹分析评估,HDL大小显著增加,LDL颗粒变小,载脂蛋白(apo)组成发生变化。CETP抑制后,大的、缺乏apoA-I且含有apoE的HDL在高胆固醇血症仓鼠中变得普遍。此外,含有CETP的HDL颗粒大小随着转运活性的抑制而增加。虽然这些效应在正常胆固醇血症动物中明显,但在天然凝胶上检测到的载脂蛋白分布和HDL亚类的变化在高胆固醇血症动物中更为显著。仓鼠中CETP抑制后HDL谱和载脂蛋白分布的变化与CETP缺陷的日本受试者中报道的变化相似,这表明高胆固醇血症仓鼠作为体内模型对于理解与CETP抑制相关的脂蛋白变化具有实用性。